


## PHARMACEUTICAL 2018

## Zyla Life Sciences Rank 207 of 349





## PHARMACEUTICAL 2018

## Zyla Life Sciences Rank 207 of 349

The relative strengths and weaknesses of Zyla Life Sciences are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zyla Life Sciences compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 88% points. The greatest weakness of Zyla Life Sciences is the variable Other Expenses, reducing the Economic Capital Ratio by 86% points.

The company's Economic Capital Ratio, given in the ranking table, is -232%, being 46% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	101,953
Cost of Goods Sold	0
Intangible Assets	6,583
Liabilities, Current	42,967
Liabilities, Non-Current	99,617
Other Assets	1,411
Other Compr. Net Income	908
Other Expenses	45,527
Other Liabilities	16,649
Other Net Income	-1,159
Property and Equipment	9,911
Research and Development	14,744
Revenues	26,136
Selling, General and Administrative Expense	34,065

Output Variable	Value in 1000 USD
Assets	119,858
Liabilities	159,233
Expenses	94,336
Stockholders Equity	-39,375
Net Income	-69,359
Comprehensive Net Income	-68,905
Economic Capital Ratio	-232%